UY24472A1 - Composiciones de agonistas/antagonistas de estrógenos y agonistas/antagonistas de prostaglandinas, útiles en el tratamiento de la osteoporosis - Google Patents

Composiciones de agonistas/antagonistas de estrógenos y agonistas/antagonistas de prostaglandinas, útiles en el tratamiento de la osteoporosis

Info

Publication number
UY24472A1
UY24472A1 UY2447224472A UY24472A UY24472A1 UY 24472 A1 UY24472 A1 UY 24472A1 UY 2447224472 A UY2447224472 A UY 2447224472A UY 24472 A UY24472 A UY 24472A UY 24472 A1 UY24472 A1 UY 24472A1
Authority
UY
Uruguay
Prior art keywords
compound
agonist
prostaglandin
therapeutically effective
antagonist
Prior art date
Application number
UY2447224472A
Other languages
English (en)
Inventor
David D Thompson
Hua Zhu Ke
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY24472A1 publication Critical patent/UY24472A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Abstract

Una composición farmacéutica que contiene: a- una Una comestos son antagonistas del receptor muscarínico, útiles para el tratamiento de, por ejemplo, cantidad terapéuticamente eficaz de un primer compuesto, siendo dicho primer compuesto un compuesto el síndrome del intestino irritable y la incontineun agonista/antagonista de estrógenos; y b- una cancia urinaria. Los compuestos también son útiles cntidad terapéuticamente eficaz de un segundo compuomo reforzadores de la cognición. Tambien son de uesto, siendo dicho compuesto una prostaglandina o tilidad en trastornos relacionados con la edad como el Alzheimer. Los compuestos de fórmula (I) dondun agonista/antagonista de una prostaglandina. Una composición como la antes mencionada, en la que ee R1 es alquilo C1-6, halo-alquilo C1-6,, cicloalquilo, etc; R2 es H o alquilo; R3 es arilo, heteroal agonista/antagonista de estrógenos es droloxifenrilo, cicloalquilo, X es O o S, Y es un enlace diro, ralixifeno, tamoxifeno, 4-hidroxi-tamoxifeno, etc y el segundo compuesto es PGD1, PGD2, PGE2, PGEecto CH2, (CH2)2 etc. Por halógeno se entiende Cl,1, Pgf2alfa y 3S-(3-hidroxi-4-fenil-butil)-2R-[6-( Br, F y I2;los grupos preferidos son fenilo y naftilo, mas preferentemente son fenilo sustituidos p1H-tetrazol-5-il)-hexil]-ciclopentanona. Un Kit quor alquilo, alcoxi, halógeno y naftilo. Los grupose contiene los siguientes elementos para ser utili heteroarilo mas preferidos son metilo, etilo. Loszados en la preparación dicha composición: a- una cantidad terapéuticamente eficaz de un agonista/an grupos alcoxi son metoxi y etoxi. Ejemplo: 3-(1,1-Difenil-1-hidroximetil)-5-(4-(1-brncilpiperidiniltagonista de estrógenos y un vehículo farmacéuticamente aceptable en una primera forma de dosificaci))-1,2,4-oxadiazol ón unitaria; b- una cantidad terapéuticamente eficaz de una prostaglandina o de un agonista/antagonista de prostaglandinas y c- un envase para contener dicha primera y segunda formas de dosificación, El uso de esta composición farmacéutica en la preparación de un medicamento para el tratamiento de una condición que se manifiesta con la presencia de masa ósea reducida, ósea para la osteoporosis.
UY2447224472A 1996-02-28 1997-02-27 Composiciones de agonistas/antagonistas de estrógenos y agonistas/antagonistas de prostaglandinas, útiles en el tratamiento de la osteoporosis UY24472A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1241296P 1996-02-28 1996-02-28

Publications (1)

Publication Number Publication Date
UY24472A1 true UY24472A1 (es) 2000-09-29

Family

ID=21754846

Family Applications (1)

Application Number Title Priority Date Filing Date
UY2447224472A UY24472A1 (es) 1996-02-28 1997-02-27 Composiciones de agonistas/antagonistas de estrógenos y agonistas/antagonistas de prostaglandinas, útiles en el tratamiento de la osteoporosis

Country Status (45)

Country Link
US (2) US6323232B1 (es)
EP (3) EP1932543A3 (es)
JP (2) JPH11504352A (es)
KR (1) KR19990087337A (es)
CN (5) CN1242813C (es)
AP (3) AP974A (es)
AR (2) AR005987A1 (es)
AT (1) ATE405273T1 (es)
AU (1) AU703285B2 (es)
BG (1) BG64582B1 (es)
BR (1) BR9612533A (es)
CA (1) CA2247420C (es)
CL (1) CL2004000119A1 (es)
CO (1) CO4761063A1 (es)
CZ (1) CZ297452B6 (es)
DE (1) DE69637651D1 (es)
DK (1) DK0883404T3 (es)
DZ (1) DZ2186A1 (es)
ES (1) ES2312169T3 (es)
GT (2) GT199700009A (es)
HK (1) HK1018210A1 (es)
HN (1) HN1996000101A (es)
HR (1) HRP970118A2 (es)
HU (1) HUP9904123A3 (es)
ID (1) ID19886A (es)
IL (3) IL154379A0 (es)
IS (1) IS4812A (es)
MA (1) MA26420A1 (es)
NO (2) NO323648B1 (es)
NZ (1) NZ323456A (es)
OA (1) OA10837A (es)
PE (2) PE20011302A1 (es)
PL (2) PL187962B1 (es)
PT (1) PT883404E (es)
RU (1) RU2190395C2 (es)
SI (1) SI0883404T1 (es)
SK (1) SK118398A3 (es)
TN (1) TNSN97040A1 (es)
TR (1) TR199801679T2 (es)
TW (1) TW464496B (es)
UA (1) UA69372C2 (es)
UY (1) UY24472A1 (es)
WO (1) WO1997031640A1 (es)
YU (1) YU7797A (es)
ZA (1) ZA971719B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
AR008155A1 (es) * 1996-09-06 1999-12-09 Smithkline Beecham Corp Uso de un compuesto de formula i para preparar un medicamento util para tratar y prevenir la enfermedad cardiovascular post menopausica en mujeres.
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
WO1998058911A2 (en) * 1997-06-23 1998-12-30 Pfizer Inc. Prostaglandin agonists
ID24759A (id) * 1997-09-09 2000-08-03 Procter & Gamble Metoda untuk meningkatkan volume tulang
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
EP0950417A3 (en) * 1998-02-23 2000-02-23 Pfizer Products Inc. Treatment of skeletal disorders
ES2235475T3 (es) * 1998-06-03 2005-07-01 Pfizer Products Inc. 2-aminopiridinas que contienen sustituyentes de anillos condensados como inhibidores de oxido nitrico sintasa.
ATE265853T1 (de) * 1998-06-16 2004-05-15 Pfizer Prod Inc Kombinationstherapeutika, enthaltend einen selektiven östrogenrezeptormodulator und prostaglandin e2
JP2002518328A (ja) * 1998-06-16 2002-06-25 ファイザー・プロダクツ・インク 筋骨格虚弱の治療用の（選択的）エストロゲン受容体モジュレーター（ｓｅｒｍ）および成長ホルモン分泌促進薬（ｇｈｓ）の治療的組合せ
AR018869A1 (es) * 1998-06-16 2001-12-12 Pfizer Prod Inc Composicion farmaceutica, su uso para la preparacion de medicamentos y estuche que la contiene
PA8471201A1 (es) * 1998-06-16 2000-09-29 Pfizer Prod Inc Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea
EP1004306A3 (en) * 1998-08-06 2000-06-07 Pfizer Products Inc. Estrogen agonists/antagonists
US6414006B1 (en) 1998-10-15 2002-07-02 Merck Frosst Canada & Co. Methods for inhibiting bone resorption
AU5995299A (en) 1998-11-03 2000-05-22 Pfizer Products Inc. Novel macrolide antibiotics
CA2365326A1 (en) * 1999-03-05 2000-09-08 The Procter & Gamble Company Methods of increasing bone volume using non-naturally-occurring fp selective agonists and antiresorptive compounds
GB9913649D0 (en) * 1999-06-11 1999-08-11 Karobio Ab Estrogen receptor
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
CO5251465A1 (es) 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
NZ516582A (en) * 2000-06-01 2004-08-27 Watson Pharmaceuticals Inc Transdermal delivery of lasofoxifene
EP1192945A3 (en) * 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
TWI303990B (en) * 2000-10-17 2008-12-11 Pfizer Prod Inc New use of estrogen agonists/antagonists for improving vascular health
ES2233570T3 (es) * 2000-11-30 2005-06-16 Pfizer Products Inc. Composicion que contiene agonistas/antagosnistas de estrogenos y testosterona para tratar un descenso en el nivel de la hormona testosterona.
WO2003011282A1 (en) * 2001-07-31 2003-02-13 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
TWI316511B (en) 2002-11-26 2009-11-01 Smithkline Beecham Corp Calcilytic compounds
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
WO2013049507A1 (en) 2011-09-30 2013-04-04 Perio Sciences, Llc Antioxidant compositions for treatment of inflammation or oxidative damage
CN103142644B (zh) * 2013-03-21 2014-07-23 青岛正大海尔制药有限公司 骨化三醇和氟化钠的混悬颗粒及其制备方法
PL3525774T3 (pl) 2016-10-11 2022-04-25 Duke University Leczenie lazofoksyfenem raka piersi er+
WO2019199891A1 (en) 2018-04-10 2019-10-17 Duke University Lasofoxifene treatment of breast cancer
CN112384634B (zh) * 2018-04-24 2024-04-16 深圳华大生命科学研究院 骨质疏松生物标志物及其用途
CN110412289B (zh) * 2019-07-25 2022-08-02 北京美迪阿姆科技发展有限公司 抑制性t细胞及筛选方法和抑制自身免疫反应中的应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274213A (en) 1961-09-05 1966-09-20 Upjohn Co Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
US3234090A (en) 1962-09-10 1966-02-08 Ciba Geigy Corp Pharmaceutical compositions comprising saturated basic ethers
BE637389A (es) 1962-09-13
US3522319A (en) 1964-01-23 1970-07-28 Ciba Geigy Corp Phenol substituted tetrahydronaphthalenes useful as estrogenics
US3822287A (en) 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
US3927197A (en) 1974-04-19 1975-12-16 Pfizer Tertiary alcohol stabilized E-series prostaglandins
US3932389A (en) 1974-12-11 1976-01-13 Pfizer Inc. 2-Descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.omega.-pentanorprostaglandins
US3982016A (en) 1975-08-06 1976-09-21 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4000309A (en) 1975-08-06 1976-12-28 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4018892A (en) 1975-08-06 1977-04-19 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4132847A (en) 1977-07-22 1979-01-02 Pfizer Inc. 4-Pyrone prostaglandin antagonists
EP0002097B1 (en) 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
US4097601A (en) 1977-08-26 1978-06-27 Pfizer Inc. Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins
US4171331A (en) 1978-06-05 1979-10-16 Miles Laboratories, Inc. 1 And 2-substituted analogues of certain prostaglandins
US4219483A (en) 1978-09-11 1980-08-26 Pfizer Inc. 4-Pyrone prostaglandin antagonists
DE3046719C2 (de) 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4621100A (en) 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US4904478A (en) 1983-08-11 1990-02-27 Mission Pharmacal Company Slow-release sodium fluoride tablet and method for treatment of osteoporosis
ATE114473T1 (de) 1984-04-30 1994-12-15 Procter & Gamble Ausrüstung für die verwendung bei der behandlung von osteoporose.
US4729999A (en) 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
EP0260066B1 (en) 1986-09-11 1990-05-09 National Research Development Corporation Tamoxifen derivatives
US5216183A (en) 1988-04-19 1993-06-01 Teijin Limited Cyclopentanone/cyclopentenone derivative
ATE150648T1 (de) * 1990-11-26 1997-04-15 Robert R Recker Behandlung von osteoporose unter verwendung von wachstumshormon-freisetzendem faktor (grf) in verbindung mit parathyroidhormon (pth)
JPH04312526A (ja) * 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5180720A (en) * 1991-05-03 1993-01-19 G. D. Searle & Co. 2- and 3-alkoxy or hydroxy-8-substituted-dibenz[b,f]-[1,4]oxazepine-10(11H)-carboxylic acid, substituted hydrazides and methods for treating pain
US5409911A (en) 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5578593A (en) 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
SK282166B6 (sk) 1992-12-11 2001-11-06 Merck & Co., Inc. Spiropiperidínové deriváty, spôsob ich výroby a farmaceutický prostriedok s ich obsahom
TW383306B (en) 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
TW303299B (es) 1993-07-22 1997-04-21 Lilly Co Eli
KR960705575A (ko) * 1993-10-19 1996-11-08 도나 엘. 폴락 비스포스포네이트와 성장 호르몬 분비촉진제와의 배합물(Combination of bishosphonates and growth hormone secretagogues)
CN1174504A (zh) 1993-11-09 1998-02-25 麦克公司 促进生长激素释放的哌啶、吡咯烷和六氢－1h－吖庚因
US5492916A (en) 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
CA2176140A1 (en) 1993-11-24 1995-06-01 Meng Hsin Chen Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)
US5441966A (en) 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting Turner's syndrome
WO1995034311A1 (en) 1994-06-13 1995-12-21 Merck & Co., Inc. Piperazine compounds promote release of growth hormone
EP0779813A4 (en) * 1994-09-09 1998-05-06 Procter & Gamble PHOSPHONATES AND PARATHORMONE AGAINST OSTEOPOROSIS
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5767124A (en) 1995-10-27 1998-06-16 Merck & Co., Inc. Polymorphic forms of a growth hormone secretagogue
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
US6100301A (en) * 1996-02-28 2000-08-08 Pfizer Inc Combination therapy to treat osteoporosis-polyphosphonates and estrogen agonists
TR199802241T2 (es) * 1996-05-07 1999-02-22 Pfizer Inc.
TW491847B (en) * 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
CN1220609A (zh) 1996-05-31 1999-06-23 诺沃挪第克公司 骨质疏松症周期性治疗中的生长激素组分和骨抗吸收剂
GB2324726A (en) 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
UA53716C2 (uk) * 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
BR9803596A (pt) 1997-09-23 2000-04-25 Pfizer Prod Inc Derivados do resorcinol.
PA8471201A1 (es) * 1998-06-16 2000-09-29 Pfizer Prod Inc Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea

Also Published As

Publication number Publication date
CO4761063A1 (es) 1999-04-27
HUP9904123A2 (hu) 2000-05-28
EP1932543A3 (en) 2012-01-04
NO20063853L (no) 1998-08-27
DZ2186A1 (fr) 2002-12-02
RU2190395C2 (ru) 2002-10-10
UA69372C2 (en) 2004-09-15
CN1242813C (zh) 2006-02-22
AP9700934A0 (en) 1997-04-30
CZ297452B6 (cs) 2006-12-13
OA10837A (en) 2001-08-13
NO983936D0 (no) 1998-08-27
BG64582B1 (bg) 2005-08-31
AP2000001962A0 (en) 2000-12-31
AP2002002661A0 (en) 2002-12-31
JP2002308771A (ja) 2002-10-23
PL187962B1 (pl) 2004-11-30
TNSN97040A1 (fr) 2005-03-15
US20010009920A1 (en) 2001-07-26
PL328831A1 (en) 1999-02-15
AP975A (en) 2001-06-12
CA2247420C (en) 2011-02-15
DE69637651D1 (en) 2008-10-02
PE20011302A1 (es) 2001-12-25
US7255984B2 (en) 2007-08-14
AR005987A1 (es) 1999-07-21
EP1236475A2 (en) 2002-09-04
JPH11504352A (ja) 1999-04-20
EP0883404A1 (en) 1998-12-16
PE58998A1 (es) 1998-10-16
PT883404E (pt) 2008-11-14
CN1515316A (zh) 2004-07-28
US6323232B1 (en) 2001-11-27
BR9612533A (pt) 1999-07-20
AU703285B2 (en) 1999-03-25
CA2247420A1 (en) 1997-09-04
BG102726A (en) 1999-04-30
ZA971719B (en) 1998-08-27
GT199700009AA (es) 1999-01-23
IL154379A0 (en) 2003-09-17
WO1997031640A1 (en) 1997-09-04
HRP970118A2 (en) 1998-04-30
DK0883404T3 (da) 2008-10-20
AR060853A2 (es) 2008-07-16
IS4812A (is) 1998-07-28
CL2004000119A1 (es) 2005-02-11
NO983936L (no) 1998-08-27
CN1515317A (zh) 2004-07-28
HK1018210A1 (en) 1999-12-17
EP1236475A3 (en) 2003-11-05
ES2312169T3 (es) 2009-02-16
EP0883404B1 (en) 2008-08-20
TR199801679T2 (xx) 2001-06-21
KR19990087337A (ko) 1999-12-27
IL125493A0 (en) 1999-03-12
SK118398A3 (en) 2000-07-11
NZ323456A (en) 2001-03-30
PL187219B1 (pl) 2004-06-30
SI0883404T1 (sl) 2008-10-31
AU1039897A (en) 1997-09-16
YU7797A (sh) 2000-10-30
CN1209064A (zh) 1999-02-24
GT199700009A (es) 1998-07-10
CN1515254A (zh) 2004-07-28
CZ271898A3 (cs) 1999-06-16
ID19886A (id) 1998-08-13
HN1996000101A (es) 1997-06-26
IL154380A0 (en) 2003-09-17
NO323648B1 (no) 2007-06-18
EP1932543A2 (en) 2008-06-18
AP1179A (en) 2003-06-30
MA26420A1 (fr) 2004-12-20
HUP9904123A3 (en) 2001-01-29
CN1515258A (zh) 2004-07-28
ATE405273T1 (de) 2008-09-15
TW464496B (en) 2001-11-21
AP974A (en) 2001-06-12

Similar Documents

Publication Publication Date Title
UY24472A1 (es) Composiciones de agonistas/antagonistas de estrógenos y agonistas/antagonistas de prostaglandinas, útiles en el tratamiento de la osteoporosis
RU2312106C2 (ru) Замещенные 4-алкоксиоксазолпроизводные в качестве агонистов ppar
RU2319701C2 (ru) ГЕТЕРОПОЛИЦИКЛИЧЕСКОЕ СОЕДИНЕНИЕ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ МЕТАБОТРОПНЫХ ГЛЮТАМАТНЫХ РЕЦЕПТОРОВ mGluR ГРУППЫ I
IL162296A (en) Composition of nanoparticles of antagonist receptor antagonist tachykinin
PE20050222A1 (es) Compuestos de triazol como antagonistas de vasopresina
ES2175480T3 (es) Composiciones limpiadoras y desinfectantes mejoradas, de tipo eflorescente.
AR036115A1 (es) Compuesto de n-aroilaminas, composiciones farmaceuticas formuladas con dichos compuestos; uso de los compuestos mencionados en la preparacion de composiciones farmaceuticas para tratar,prevenir enfermedades o trastornos donde se requiere la aplicacion de antagonistas de receptores de la orexina huma
BR0317294A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários
DK1355646T3 (da) Muscariniske receptoragonister
PE20030702A1 (es) Inhibidores de pde9 para tratamiento de transtornos cardiovasculares
ES2168237T1 (es) Pirazolopirimidinas que actuan como antagonistas del receptor del crf.
AR033306A1 (es) Compuestos
PE20060150A1 (es) Antagonistas de cgrp seleccionados, composiciones farmaceuticas y procedimiento para su preparacion
BR0211201A (pt) Composto, processo para a preparação desse composto, sua utilização, composição farmacêutica que compreende o mesmo e método para o tratamento de uma enfermidade em um mamìfero
PE20050420A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
PE20070355A1 (es) Antagonistas de cgrp seleccionados y procedimientos para su preparacion
KR960037675A (ko) 벤조니트릴 및 벤조플루오라이드
KR920009828A (ko) 신규의 삼환식 화합물
AR034174A1 (es) Compuestos de benzoxazinona, procedimiento para su preparacion, composiciones farmaceuticas que lo comprenden, procedimiento para la preparacion de tales composiciones, y el uso de dichos compuestos o composiciones en la fabricacion de medicamentos
PT87073A (pt) 4-]4-]4-]4-]]2-(2,4-difluorophenyl)-2-(1h-azolylmethyl)-1,3-dioxolan-4-yl"methoxy"phenyl"-1-piperazinyl"phenyl"triazolones
AR015446A1 (es) Antagonistas de receptores de vitronectina, composicion farmaceutica que los contiene, procedimiento para su preparacion, su uso para la elaboracion de unmedicamento y compuestos intermediarios
PE20050587A1 (es) Derivados de diazindol-dicarbonilo-piperazinilo como agentes antivirales
AR005916A1 (es) Compuestos de oxadiazol, y de tiadiazol, su uso, procedimientos para prepararlos, composiciones farmaceuticas que los contienen y un compuesto util como intermedio
BR0212353A (pt) Composto, composição farmacêutica, e, uso de um composto
DK67682A (da) Fremgangsmaade til fremstilling af substituerede 3-aminosydnoniminer eller syreadditionssalte deraf samt disse forbindelsers anvendelse mod cardiovaskulaere sygdomme

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20170227